Phase 2 Study of Panzem速 NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma
This open-label, multicenter, Phase 2 trial, will assess the anti tumor activity, safety and pharmacodynamics, of Panzem速 NCD with or without Sunitinib Malate in patients with metastatic renal cell carcinoma progressing on Sunitinib Malate.
Metastatic Renal Cell Carcinoma
DRUG: Panzem速 NCD|DRUG: Sunitinib Malate
To assess the objective response rate of Panzem NCD alone and in combination with Sunitinib Malate, Throughout study participation
This open-label, multicenter, Phase 2 trial, will assess the anti tumor activity, safety and pharmacodynamics, of Panzem速 NCD with or without Sunitinib Malate in patients with metastatic renal cell carcinoma progressing on Sunitinib Malate.